Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
STAT3 plays a vital role in maintaining the self-renewal of tumor stem cells. BBI608, a small molecule identified by its ability to inhibit gene transcription driven by STAT3 and cancer stemness properties, can inhibit stemness gene expression and kill stemness-high cancer cells isolated from a variety of cancer types. In order to improve the pharmacokinetic properties of BBI608 and the antitumor activity, a series of BBI608 derivatives were designed and synthesized here. Most of these compounds were more potent than BBI608 on HepG2 cells, compound LD-8 had the most potent inhibitory activity among them and was 5.4-fold more potent than BBI608 (IC = 11.2 μM), but had considerable activity on normal liver cells L-02. Compounds LD-17 (IC = 3.5 μM) and LD-19 (IC = 2.9 μM) were found to possess significant inhibitory activities and good selectivity. The results showed that compound LD-19 was worthy to investigate further as a lead compound according to its potent inhibitory activity, ideal ClogP value and better water solubility.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2018.03.054 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Juglone Derivatives as Novel STAT3 Inhibitors with Potent Suppression of Cancer Cell Stemness against Breast Cancer.
J Med Chem
July 2025
State Key Laboratory of Natural Medicines, China Pharmaceutical University, No. 639 Longmian Dadao, Nanjing 211198, China.
Breast cancer stem cells (BCSCs) are pivotal in tumor initiation, progression, and therapeutic resistance, underscoring the need for targeted interventions. Signal transducer and activator of transcription 3 (STAT3) has been implicated in maintaining cancer stemness, representing a compelling therapeutic target. Here, we describe the structure-guided optimization of Juglone, yielding novel STAT3 inhibitors with improved potency.
View Article and Find Full Text PDFTargeting stemness pathways modulates macrophage polarization and reprograms the tumor microenvironment.
Front Immunol
May 2025
Laboratory of Immunology, National Cancer Institute, Vilnius, Lithuania.
Introduction: The tumor microenvironment plays a pivotal role in cancer progression and therapeutic resistance, with tumor-associated macrophages significantly influencing immune suppression and tumor growth. Colorectal cancers (CRC) classified as Consensus Molecular Subtype 4 (CMS4) and triple-negative breast cancers subsets are particularly characterized by a mesenchymal phenotype, immune exclusion, and extensive macrophage infiltration. This study aimed to investigate how targeting cancer cell stemness with specific inhibitors could modulate macrophage polarization in CRC and breast cancer , potentially shifting the immune balance from pro-tumor M2-like to anti-tumor M1-like macrophages.
View Article and Find Full Text PDFFormosanin C inhibits triple-negative breast cancer progression by suppressing the phosphorylation of STAT3 and the polarization of M2 macrophages.
Breast Cancer Res Treat
May 2025
Department of Breast Surgery, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Introduction: Triple-negative breast cancer (TNBC), is a highly aggressive tumor. Formosanin C (FC) is a diosgenin with immunomodulatory and antitumor properties, the precise mechanism through which it is against TNBC remains uncertain.
Objective: Clarifying the mechanism of FC against TNBC.
Discovery of naphthoquinone-furo-piperidone derivatives as dual targeting agents of STAT3 and NQO1 for the treatment of breast cancer.
Eur J Med Chem
April 2025
College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China; Jinhua Institute of Zhejiang University, Jinhua, 321299, China; Department of Burns and Wound Care, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China. Electronic address:
Breast cancer is one of the most common malignancies in women, posing a significant threat to their physical and mental well-being. STAT3 has been found closely associated with the occurrence and development of breast cancer, while blocking STAT3 pathway can promote apoptosis of breast cancer cells and inhibit cell proliferation. NQO1 is a potential anti-tumor drug target, and its substrate has been widely proven to show significant anti-tumor activity.
View Article and Find Full Text PDFDesign, synthesis, and biological evaluation of novel (E)-2-cyano-3-(4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-2-yl) derivatives as potent STAT3-targeting anticolorectal cancer agents.
Bioorg Chem
December 2024
Laboratory of Human Diseases and Immunotherapy, West China Hospital, Sichuan University, Chengdu 610041, China; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China; Department of Cardiovascular Surgery, West China Hospital, Sichuan Uni
Dysregulation of signal transducer and activator of transcription 3 (STAT3) is implicated in the pathogenesis of various cancers, underscoring its potential as a cancer therapeutic target. In this work, we designed and synthesized a novel series of (E)-2-cyano-3-(4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-2-yl) derivatives and evaluated their anti-proliferative effects on tumour cells. Among these derivatives, NW16 exhibited remarkable antiproliferative activity against HCT116 cells, with an IC value of 0.
View Article and Find Full Text PDF